Contrast-induced nephropathy: Protective role of fenoldopam

Clinical and Experimental Pharmacology and Physiology

Volumn 39, Issue 6, 2012, Pages 497-505

  Caixeta, Adriano ^a   Dogan, Ozgen ^a   Weisz, Giora ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Contrast induced nephropathy; Fenoldopam; Targeted renal therapy

Indexed keywords

DOPAMINE; FENOLDOPAM; PLACEBO;

CONTRAST INDUCED NEPHROPATHY; DRUG ADMINISTRATION ROUTE; DRUG DOSE TITRATION; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; INFUSION SYSTEM; INTRARENAL DRUG ADMINISTRATION; KIDNEY; LOW DRUG DOSE; PATHOGENESIS; RENAL ARTERY; REVIEW;

ACUTE KIDNEY INJURY; ANIMALS; CLINICAL TRIALS AS TOPIC; CONTRAST MEDIA; FENOLDOPAM; HUMANS; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; VASODILATOR AGENTS;

EID: 84861655296     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2012.05707.x     Document Type: Review

References (112)

1. Parfrey PS, Griffiths SM, Barrett BJ, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N. Engl. J. Med. 1989; 320: 143-9.
2. Hou SH, Bushinsky DA, Wish JB, Cohen JJ, Harrington JT. Hospital-acquired renal insufficiency: A prospective study. Am. J. Med. 1983; 74: 243-8.
3. Gruberg L, Mintz GS, Mehran R, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J. Am. Coll. Cardiol. 2000; 36: 1542-8.
4. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. Am. J. Med. 1997; 103: 368-75.
5. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996; 275: 1489-94.
6. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105: 2259-64.
7. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am. J. Kidney Dis. 2002; 39: 930-6.
8. Solomon R, Deray G. How to prevent contrast-induced nephropathy and manage risk patients: Practical recommendations. Kidney Int. Suppl. 2006; 100: S51-3.
9. Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. J. Am. Soc. Nephrol. 2000; 11: 177-82.
10. Maeder M, Klein M, Fehr T, Rickli H. Contrast nephropathy. Review focusing on prevention. J. Am. Coll. Cardiol. 2004; 44: 1763-71.
11. Goldenberg I, Matetzky S. Nephropathy induced by contrast media: Pathogenesis, risk factors and preventive strategies. CMAJ 2005; 172: 1461-71.
12. Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study. Arch. Intern. Med. 1990; 150: 1237-42.
13. Gleeson TG, Bulugahapitiya S. Contrast-induced nephropathy. Am. J. Roentgenol. 2004; 183: 1673-89.
14. Mehran R, Nikolsky E. Contrast-induced nephropathy: Definition, epidemiology, and patients at risk. Kidney Int. Suppl. 2006; 100: S11-5.
15. Cochran ST, Wong WS, Roe DJ. Predicting angiography-induced acute renal function impairment: Clinical risk model. Am. J. Roentgenol. 1983; 141: 1027-33.
16. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: Development and initial validation. J. Am. Coll. Cardiol. 2004; 44: 1393-9.
17. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N. Engl. J. Med. 1994; 331: 1416-20.
18. Bader BD, Berger ED, Heede MB, et al. What is the best hydration regimen to prevent contrast media-induced nephrotoxicity? Clin. Nephrol. 2004; 62: 1-7.
19. Krasuski RA, Beard BM, Geoghagan JD, Thompson CM, Guidera SA. Optimal timing of hydration to erase contrast-associated nephropathy: The OTHER CAN study. J. Invasive Cardiol. 2003; 15: 699-702.
20. Hall KA, Wong RW, Hunter GC, et al. Contrast-induced nephrotoxicity: The effects of vasodilator therapy. J. Surg. Res. 1992; 53: 317-20.
21. Chertow GM, Sayegh MH, Allgren RL, Lazarus JM. Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure? Auriculin Anaritide Acute Renal Failure Study Group Am. J. Med. 1996; 101: 49-53.
22. Wang A, Holcslaw T, Bashore TM, et al. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int. 2000; 57: 1675-80.
23. Kurnik BR, Allgren RL, Genter FC, Solomon RJ, Bates ER, Weisberg LS. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am. J. Kidney Dis. 1998; 31: 674-80.
24. Abizaid AS, Clark CE, Mintz GS, et al. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am. J. Cardiol. 1999; 83: 260-3.
25. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: A randomized controlled trial. JAMA 2004; 291: 2328-34.
26. Briguori C, Airoldi F, D'Andrea D, et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): A randomized comparison of 3 preventive strategies. Circulation 2007; 115: 1211-7.
27. Stone GW, McCullough PA, Tumlin JA, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: A randomized controlled trial. JAMA 2003; 290: 2284-91.
28. Misra D, Leibowitz K, Gowda RM, Shapiro M, Khan IA. Role of N-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures: A meta-analysis. Clin. Cardiol. 2004; 27: 607-10.
29. Alonso A, Lau J, Jaber BL, Weintraub A, Sarnak MJ. Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: A meta-analysis of randomized, controlled trials. Am. J. Kidney Dis. 2004; 43: 1-9.
30. Bagshaw SM, Ghali WA. Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: A systematic review and meta-analysis. BMC Med. 2004; 2: 38.
31. Kshirsagar AV, Poole C, Mottl A, et al. N-Acetylcysteine for the prevention of radiocontrast induced nephropathy: A meta-analysis of prospective controlled trials. J. Am. Soc. Nephrol. 2004; 15: 761-9.
32. Birck R, Krzossok S, Markowetz F, Schnulle P, van der Woude FJ, Braun C. Acetylcysteine for prevention of contrast nephropathy: Meta-analysis. Lancet 2003; 362: 598-603.
33. Pannu N, Manns B, Lee H, Tonelli M. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int. 2004; 65: 1366-74.
34. Isenbarger DW, Kent SM, O'Malley PG. Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am. J. Cardiol. 2003; 92: 1454-8.
35. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Meta-analysis: Effectiveness of drugs for preventing contrast-induced nephropathy. Ann. Intern. Med. 2008; 148: 284-94.
36. Jo SH, Koo BK, Park JS, et al. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial: A randomized controlled study. Am. Heart J. 2008; 155: 499e1-8.
37. Brar SS, Shen AY, Jorgensen MB, et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: A randomized trial. JAMA 2008; 300: 1038-46.
38. Spargias K, Adreanides E, Demerouti E, et al. Iloprost prevents contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 2009; 120: 1793-9.
39. Adolph E, Holdt-Lehmann B, Chatterjee T, et al. Renal Insufficiency Following Radiocontrast Exposure Trial (REINFORCE): A randomized comparison of sodium bicarbonate versus sodium chloride hydration for the prevention of contrast-induced nephropathy. Coron. Artery Dis. 2008; 19: 413-9.
40. From AM, Bartholmai BJ, Williams AW, Cha SS, Pflueger A, McDonald FS. Sodium bicarbonate is associated with an increased incidence of contrast nephropathy. A retrospective cohort study of 7977 patients at Mayo clinic. Clin. J. Am. Soc. Nephrol. 2008; 3: 10-8.
41. Sendeski MM. Pathophysiology of renal tissue damage by iodinated contrast media. Clin. Exp. Pharmacol. Physiol. 2011; 38: 292-9.
42. Weisberg LS, Kurnik PB, Kurnik BR. Radiocontrast-induced nephropathy in humans: Role of renal vasoconstriction. Kidney Int. 1992; 41: 1408-15.
43. Brezis M, Rosen S, Silva P, Epstein FH. Selective vulnerability of the medullary thick ascending limb to anoxia in the isolated perfused rat kidney. J. Clin. Invest. 1984; 73: 182-90.
44. Tumlin J, Stacul F, Adam A, et al. Pathophysiology of contrast-induced nephropathy. Am. J. Cardiol. 2006; 98: K14-20.
45. Klause N, Arendt T, Lins M, Gronow G. Hypoxic renal tissue damage by endothelin-mediated arterial vasoconstriction during radioangiography in man. Adv. Exp. Med. Biol. 1998; 454: 225-34.
46. Fujisaki K, Kubo M, Masuda K, et al. Infusion of radiocontrast agents induces exaggerated release of urinary endothelin in patients with impaired renal function. Clin. Exp. Nephrol. 2003; 7: 279-83.
47. 1 receptors in contrast media-induced renal dysfunction in the normal rat. Eur. Radiol. 2004; 14: 1297-302.
48. Rauch D, Drescher P, Pereira FJ, Knes JM, Will JA, Madsen PO. Comparison of iodinated contrast media-induced renal vasoconstriction in human, rabbit, dog, and pig arteries. Invest. Radiol. 1997; 32: 315-9.
49. Morris TW, Katzberg RW, Fischer HW. A comparison of the hemodynamic responses to metrizamide and meglumine/sodium diatrizoate in canine renal angiography. Invest. Radiol. 1978; 13: 74-8.
50. Bakris GL, Burnett JC Jr. A role for calcium in radiocontrast-induced reductions in renal hemodynamics. Kidney Int. 1985; 27: 465-8.
51. Tumlin JA, Wang A, Murray PT, Mathur VS. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: A pilot trial in the prevention of contrast nephropathy. Am. Heart J. 2002; 143: 894-903.
52. Russo D, Minutolo R, Cianciaruso B, Memoli B, Conte G, De Nicola L. Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. J. Am. Soc. Nephrol. 1995; 6: 1451-8.
53. Heyman SN, Brezis M, Reubinoff CA, et al. Acute renal failure with selective medullary injury in the rat. J. Clin. Invest. 1988; 82: 401-12.
54. Heyman SN, Rosen S, Khamaisi M, Idee JM, Rosenberger C. Reactive oxygen species and the pathogenesis of radiocontrast-induced nephropathy. Invest. Radiol. 2010; 45: 188-95.
55. Persson PB, Tepel M. Contrast medium-induced nephropathy: The pathophysiology. Kidney Int. Suppl. 2006; 100: S8-10.
56. Vlassara H, Uribarri J, Ferrucci L, et al. Identifying advanced glycation end products as a major source of oxidants in aging. Implications for the management and/or prevention of reduced renal function in elderly persons. Semin. Nephrol. 2009; 29: 594-603.
57. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: An emerging threat to patient outcome. Nephrol. Dial. Transplant. 2003; 18: 1272-80.
58. Scott JA, King GL. Oxidative stress and antioxidant treatment in diabetes. Ann. N. Y. Acad. Sci. 2004; 1031: 204-13.
59. Agmon Y, Peleg H, Greenfeld Z, Rosen S, Brezis M. Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. J. Clin. Invest. 1994; 94: 1069-75.
60. Ribeiro L, de Assuncao e Silva F, Kurihara RS, Schor N, Mieko E, Higa S. Evaluation of the nitric oxide production in rat renal artery smooth muscle cells culture exposed to radiocontrast agents. Kidney Int. 2004; 65: 589-96.
61. Messana JM, Cieslinski DA, Humes HD. Comparison of toxicity of radiocontrast agents to renal tubule cells in vitro. Renal Fail. 1990; 12: 75-82.
62. Katholi RE, Woods WT Jr, Taylor GJ, et al. Oxygen free radicals and contrast nephropathy. Am. J. Kidney Dis. 1998; 32: 64-71.
63. Bakris GL, Lass NA, Glock D. Renal hemodynamics in radiocontrast medium-induced renal dysfunction: A role for dopamine-1 receptors. Kidney Int. 1999; 56: 206-10.
64. Deray G, Baumelou B, Martinez F, Brillet G, Jacobs C. Renal vasoconstriction after low and high osmolar contrast agents in ischemic and non ischemic canine kidney. Clin. Nephrol. 1991; 36: 93-6.
65. Pucelikova T, Dangas G, Mehran R. Contrast-induced nephropathy. Catheter. Cardiovasc. Interv. 2008; 71: 62-72.
66. Hizoh I, Haller C. Radiocontrast-induced renal tubular cell apoptosis: Hypertonic versus oxidative stress. Invest. Radiol. 2002; 37: 428-34.
67. Romano G, Briguori C, Quintavalle C, et al. Contrast agents and renal cell apoptosis. Eur. Heart J. 2008; 20: 2569-76.
68. McCullough PA. Contrast-induced acute kidney injury. J. Am. Coll. Cardiol. 2008; 51: 1419-28.
69. Baines AD, Ho P, Drangova R. Proximal tubular dopamine production regulates basolateral Na-K-ATPase. Am. J. Physiol. 1992; 262: F566-71.
70. Chen C, Lokhandwala MF. Inhibition of Na+, K(+)-ATPase in rat renal proximal tubules by dopamine involved DA-1 receptor activation. Naunyn Schmiedebergs Arch. Pharmacol. 1993; 347: 289-95.
71. Salomone LJ, Howell NL, McGrath HE, et al. Intrarenal dopamine D1-like receptor stimulation induces natriuresis via an angiotensin type-2 receptor mechanism. Hypertension 2007; 49: 155-61.
72. Ragsdale NV, Lynd M, Chevalier RL, Felder RA, Peach MJ, Carey RM. Selective peripheral dopamine-1 receptor stimulation. Differential responses to sodium loading and depletion in humans. Hypertension 1990; 15: 914-21.
73. Boppana VK, Dolce KM, Cyronak MJ, Ziemniak JA. Simplified procedures for the determination of fenoldopam and its metabolites in human plasma by high-performance liquid chromatography with electrochemical detection: Comparison of manual and robotic sample preparation methods. J. Chromatogr. 1989; 487: 385-99.
74. Schwartz LB, Gewertz BL. The renal response to low dose dopamine. J. Surg. Res. 1988; 45: 574-88.
75. Goldberg LI. Dopamine and new dopamine analogs. Receptors and clinical applications. J. Clin. Anesth. 1988; 1: 66-74.
76. Olsen NV, Olsen MH, Bonde J, et al. Dopamine natriuresis in salt-repleted, water-loaded humans: A dose-response study. Br. J. Clin. Pharmacol. 1997; 43: 509-20.
77. Carey RM, Siragy HM, Ragsdale NV, et al. Dopamine-1 and dopamine-2 mechanisms in the control of renal function. Am. J. Hypertens. 1990; 3: S59-63.
78. Heyman SN, Kaminski N, Brezis M. Dopamine increases renal medullary blood flow without improving regional hypoxia. Exp. Nephrol. 1995; 3: 331-7.
79. Olsen NV, Hansen JM, Ladefoged SD, Fogh-Andersen N, Leyssac PP. Renal tubular reabsorption of sodium and water during infusion of low-dose dopamine in normal man. Clin. Sci. 1990; 78: 503-7.
80. Lokhandwala MF, Amenta F. Anatomical distribution and function of dopamine receptors in the kidney. FASEB J. 1991; 5: 3023-30.
81. Jose PA, Raymond JR, Bates MD, Aperia A, Felder RA, Carey RM. The renal dopamine receptors. J. Am. Soc. Nephrol. 1992; 2: 1265-78.
82. O'Connell DP, Ragsdale NV, Boyd DG, Felder RA, Carey RM. Differential human renal tubular responses to dopamine type 1 receptor stimulation are determined by blood pressure status. Hypertension 1997; 29: 115-22.
83. Shusterman NH, Elliott WJ, White WB. Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function. Am. J. Med. 1993; 95: 161-8.
84. Mathur VS, Swan SK, Lambrecht LJ, et al. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit. Care Med. 1999; 27: 1832-7.
85. Kien ND, Moore PG, Jaffe RS. Cardiovascular function during induced hypotension by fenoldopam or sodium nitroprusside in anesthetized dogs. Anesth. Analg. 1992; 74: 72-8.
86. Satoh T, Cohen HT, Katz AI. Intracellular signaling in the regulation of renal Na-K-ATPase. I. Role of cyclic AMP and phospholipase A2. J. Clin. Invest. 1992; 89: 1496-500.
87. Brezis M, Rosen S. Hypoxia of the renal medulla: Its implications for disease. N. Engl. J. Med. 1995; 332: 647-55.
88. Murphy MB, McCoy CE, Weber RR, Frederickson ED, Douglas FL, Goldberg LI. Augmentation of renal blood flow and sodium excretion in hypertensive patients during blood pressure reduction by intravenous administration of the dopamine1 agonist fenoldopam. Circulation 1987; 76: 1312-8.
89. White WB, Halley SE. Comparative renal effects of intravenous administration of fenoldopam mesylate and sodium nitroprusside in patients with severe hypertension. Arch. Intern. Med. 1989; 149: 870-4.
90. Bodmann KF, Troster S, Clemens R, Schuster HP. Hemodynamic profile of intravenous fenoldopam in patients with hypertensive crisis. Clin. Invest. 1993; 72: 60-4.
91. Singer I, Epstein M. Potential of dopamine A-1 agonists in the management of acute renal failure. Am. J. Kidney Dis. 1998; 31: 743-55.
92. Landoni G, Biondi-Zoccai GG, Marino G, et al. Fenoldopam reduces the need for renal replacement therapy and in-hospital death in cardiovascular surgery: A meta-analysis. J. Cardiothorac. Vasc. Anesth. 2008; 22: 27-33.
93. Kapoor A, Sinha N, Sharma RK, et al. Use of dopamine in prevention of contrast induced acute renal failure: A randomised study. Int. J. Cardiol. 1996; 53: 233-6.
94. Gare M, Haviv YS, Ben-Yehuda A, et al. The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography. J. Am. Coll. Cardiol. 1999; 34: 1682-8.
95. Hans B, Hans SS, Mittal VK, Khan TA, Patel N, Dahn MS. Renal functional response to dopamine during and after arteriography in patients with chronic renal insufficiency. Radiology 1990; 176: 651-4.
96. Hans SS, Hans BA, Dhillon R, Dmuchowski C, Glover J. Effect of dopamine on renal function after arteriography in patients with pre-existing renal insufficiency. Am. Surg. 1998; 64: 432-6.
97. Weisberg LS, Kurnik PB, Kurnik BR. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int. 1994; 45: 259-65.
98. Kini AA, Sharma SK. Managing the high-risk patient: Experience with fenoldopam, a selective dopamine receptor agonist, in prevention of radiocontrast nephropathy during percutaneous coronary intervention. Rev. Cardiovasc. Med. 2001; 2 (Suppl. 1): S19-25.
99. Kini AS, Mitre CA, Kamran M, et al. Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam. Am. J. Cardiol. 2002; 89: 999-1002.
100. Kini AS, Mitre CA, Kim M, Kamran M, Reich D, Sharma SK. A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: Effect of selective dopamine receptor agonist fenoldopam. Catheter Cardiovasc. Interv. 2002; 55: 169-73.
101. Madyoon H, Croushore L, Weaver D, Mathur V. Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients. Catheter Cardiovasc. Interv. 2001; 53: 341-5.
102. Briguori C, Colombo A, Airoldi F, et al. N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity. J. Am. Coll. Cardiol. 2004; 44: 762-5.
103. Allaqaband S, Tumuluri R, Malik AM, et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc. Interv. 2002; 57: 279-83.
104. Ng MK, Tremmel J, Fitzgerald PJ, Fearon WF. Selective renal arterial infusion of fenoldopam for the prevention of contrast-induced nephropathy. J. Interv. Cardiol. 2006; 19: 75-9.
105. Allie DE, Hebert CJ, Walker CM. Multifactorial acute renal failure treated with percutaneous targeted renal therapy (TRT). A case of 'dialysis rescue'. J. Invasive Cardiol. 2007; 19: E27-30.
106. Teirstein PS, Price MJ, Mathur VS, Madyoon H, Sawhney N, Baim DS. Differential effects between intravenous and targeted renal delivery of fenoldopam on renal function and blood pressure in patients undergoing cardiac catheterization. Am. J. Cardiol. 2006; 97: 1076-81.
107. Cohen MG. First experience with intra-renal fenoldopam in a patient with heart failure. J. Invasive Cardiol. 2005; 17: 274-6.
108. Allie DE, Lirtzman MD, Wyatt CH, et al. Targeted renal therapy and contrast-induced nephropathy during endovascular abdominal aortic aneurysm repair: Results of a feasibility pilot trial. J. Endovasc. Ther. 2007; 14: 520-7.
109. Allie D, Hebert C, Patlola R, Walker CM. Contrast-induced nephropathy & targeted renal therapy in peripheral vascular disease: An 18-month experience. Am. J. Cardiol. 2008; 102: 226i (Abstract).
110. Allie DE, Hebert JC, Lirtzman MD, Wyatt CH, Walker CM. Targeted renal therapy in high-risk cardiac surgery: Early safety and feasibility with a novel catheter treatment for renal function preservation during high-risk coronary artery bypass grafting. Am. J. Cardiol. 2008; 102: 118i (Abstract).
111. Weisz G, Filby SJ, Cohen MG, et al. Safety and performance of targeted renal therapy: The Be-RITe! Registry. J. Endovasc. Ther. 2009; 16: 1-12.
112. Chamsuddin AA, Kowalik KJ, Bjarnason H, et al. Using dopamine type 1A receptor agonist in high-risk patients to ameliorate contrast-associated nephropathy. Am. J. Roentgenol. 2002; 179: 591-6.